Verrica Pharmaceuticals Strives for Nasdaq Compliance
Company Announcements

Verrica Pharmaceuticals Strives for Nasdaq Compliance

The latest announcement is out from Verrica Pharmaceuticals ( (VRCA) ).

Verrica Pharmaceuticals Inc. finds itself temporarily non-compliant with Nasdaq’s independent director requirement following the immediate resignation of board member Craig Ballaron. The company has appointed Diem Nguyen to the Audit Committee, signaling steps toward rectifying the issue. Nasdaq has granted a cure period for compliance, which extends until the company’s next annual stockholders meeting or October 2, 2025, whichever comes first. If the meeting occurs before March 31, 2025, the company must comply by that date. Verrica Pharmaceuticals is confident it will meet the requirements within the provided timeframe.

See more data about VRCA stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyOptinose names Terry Kohler as CFO
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App